Cost Drivers Report 2023
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.
Resources
We play an active role in breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Our team produces media releases, reports, policy papers and other informative content to keep you up to date on the most pressing issues facing our industry. Here in our resources section, you’ll find our most recent work.
ANALYSIS & REPORTS
Value of Medicines in Canada
This study examines and quantifies the value of innovative treatments in Canada to patient lives, the healthcare system and to society. Case studies include: HPV vaccines, Melanoma treatments, treatment for Rheumatoid Arthritis and Hepatitis C.
Cost of A Private Drug Plan Claim
IMC contracted Reformulary Group to analyze the cost of a private plan prescription drug claim in Canada, and separately in Quebec. This report summarizes that analysis.
RESEARCH
Bluesky Project
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022
2022 Code of Ethical Practices
Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to the Code is a condition of membership.
INFOGRAPHICS & DATA
Two years is too long – Understanding Canada’s Drug Access Pathway
Canadians wait two years for access to new medicines through our public drug plans. That’s a full year longer than patients in most other peer countries. Two years can feel like a lifetime for a patient waiting for access to life-saving medicines or treatments.
Canadian Drug Access Pathway
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (732 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
Better Access Better Health
More than 23-million Canadians depend on access to medicines and vaccines through employer-sponsored private plans.
RELATED LINKS
Search for Specific Brand Name Drug Negotiations Status with the pCPA
Use this tool to search for brand name drugs to view their current negotiation status.
pCPA overview of the Negotiation Process
Learn more about the negotiation process from the pCPA.
Canadian Public Reimbursement Timelines
One of Innovative Medicines Canada’s guiding principles is to offer solutions to challenges in the Canadian health system. Access to new medicines is one such challenge.
Pharma 101
Use this beginner’s guide to understand the basics of how our industry works.
Advocacy
Everything you need to make an informed decision about our industry.
Newsroom
Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
